Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthijs Monnikhof

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Neuro-Oncology Advances|May 16, 2025
Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancerMyrthe J A Koppers, Matthijs Monnikhof, Jan Meeldijk, et al.
Neuro-Oncology|October 11, 2022
Cellular immunotherapy for medulloblastomaMichael Y Schakelaar, Matthijs Monnikhof, Sandra Crnko, et al.
Neuro-Oncology Advances|January 10, 2025
Post-intrathecal chemotherapy-related paraplegia syndrome in hematological cancer patients: A systematic reviewMatthijs Monnikhof, Gabriella Hamming, Sandra Crnko, et al.
Neuro-Oncology Advances|July 24, 2025
Dual targeting of <i>CD155</i>/<i>TIGIT</i> and <i>PD-L1</i>/<i>PD-1</i> immune checkpoints potentiates NK cell-mediated cytotoxicity in medulloblastomaMatthijs Monnikhof, Michael Y Schakelaar, Chris Meulenbroeks, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Neuro-Oncology Advances|May 16, 2025
Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancerMyrthe J A Koppers, Matthijs Monnikhof, Jan Meeldijk, et al.
Neuro-Oncology|October 11, 2022
Cellular immunotherapy for medulloblastomaMichael Y Schakelaar, Matthijs Monnikhof, Sandra Crnko, et al.
Neuro-Oncology Advances|January 10, 2025
Post-intrathecal chemotherapy-related paraplegia syndrome in hematological cancer patients: A systematic reviewMatthijs Monnikhof, Gabriella Hamming, Sandra Crnko, et al.
Neuro-Oncology Advances|July 24, 2025
Dual targeting of <i>CD155</i>/<i>TIGIT</i> and <i>PD-L1</i>/<i>PD-1</i> immune checkpoints potentiates NK cell-mediated cytotoxicity in medulloblastomaMatthijs Monnikhof, Michael Y Schakelaar, Chris Meulenbroeks, et al.
Pageof 1